CSIMarket
 


Intellia Therapeutics Inc   (NTLA)
Other Ticker:  
 
 

NTLA's EPS from Cont. Operations Growth by Quarter and Year

Intellia Therapeutics Inc 's EPS from Cont. Operations results by quarter and year




NTLA EPS from Cont. Operations (in $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -1.40 -1.09 -0.69
III Quarter September -1.38 -1.49 -0.97 -0.47
II Quarter June -1.40 -1.33 -1.01 -0.61
I Quarter March -1.17 -1.96 -0.69 -0.63
FY   -3.95 -6.18 -3.76 -2.40



NTLA EPS from Cont. Operations third quarter 2023 Y/Y Growth Comment
Intellia Therapeutics Inc in the third quarter 2023 recorded EPS loss from Cont. Operations of $ -1.38 .

According to the results reported in the third quarter 2023, Intellia Therapeutics Inc achieved the best EPS from Cont. Operations growth in In Vitro & In Vivo Diagnostic Substances industry. While Intellia Therapeutics Inc ' s EPS from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2023.




NTLA EPS from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Intellia Therapeutics Inc 's third quarter 2023 EPS from Cont. Operations $ -1.38 NTLA's Income Statement
Intellia Therapeutics Inc 's third quarter 2022 EPS from Cont. Operations $ -1.49 Quarterly NTLA's Income Statement
New: More NTLA's historic EPS from Cont. Operations Growth >>


NTLA EPS from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




EPS from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
EPS from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

EPS from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Intellia Therapeutics Inc 's Q/Q EPS from Cont. Operations Growth


EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


NTLA's III. Quarter Q/Q EPS from Cont. Operations Comment
Despite the fact, that Intellia Therapeutics Inc in the III. Quarter 2023 showed EPS loss from Cont. Operations of $ -1.38 , management said, that current results point to improvement relative to the -1.40 in the second quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Intellia Therapeutics Inc achieved highest sequential EPS from Cont. Operations growth. While Intellia Therapeutics Inc 's EPS from Cont. Operations growth quarter on quarter, overall rank is .


EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


NTLA's III. Quarter Q/Q EPS from Cont. Operations Comment
Although Intellia Therapeutics Inc in the III. Quarter 2023 admitted EPS loss from Cont. Operations of $ -1.38 , it should be said, that those numbers show slight up side in contrast to the -1.40 in the second quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Intellia Therapeutics Inc achieved highest sequential EPS from Cont. Operations growth. While Intellia Therapeutics Inc 's EPS from Cont. Operations growth quarter on quarter, overall rank is .


Intellia Therapeutics Inc 's 12 Months EPS from Cont. Operations Growth Year on Year


EPS from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative EPS from Cont. Operations 12 Months Ending $ -5.35 $ -5.46 $ -5.39 $ -6.18 $ -5.87
Y / Y EPS from Cont. Operations Growth (TTM) - - - - -
Year on Year EPS from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential EPS from Cont. Operations Change (TTM) - - - - -
Seq. EPS from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative EPS from Cont. Operations growth Comment


Intellia Therapeutics Inc achieved highest trailing twelve month year on year EPS from Cont. Operations growth. While overall EPS from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative EPS from Cont. Operations growth Comment


Intellia Therapeutics Inc achieved highest trailing twelve month year on year EPS from Cont. Operations growth. While overall EPS from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other EPS from Cont. Operations Growth
In Vitro & In Vivo Diagnostic Substances Industry EPS from Cont. Operations Growth Trends and Statistics
Healthcare Sector EPS from Cont. Operations Growth Statistics
EPS from Cont. Operations Growth Trends for overall market
NTLA's EPS from Cont. Operations Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking EPS from Cont. Operations Growth
Lowest Ranking EPS from Cont. Operations Growth
EPS from Cont. Operations Growth for NTLA's Competitors
EPS from Cont. Operations Growth for Intellia Therapeutics Inc 's Suppliers
EPS from Cont. Operations Growth for NTLA's Customers

You may also want to know
NTLA's Annual Growth Rates NTLA's Profitability Ratios NTLA's Asset Turnover Ratio NTLA's Dividend Growth
NTLA's Roe NTLA's Valuation Ratios NTLA's Financial Strength Ratios NTLA's Dividend Payout Ratio
NTLA's Roa NTLA's Inventory Turnover Ratio NTLA's Growth Rates NTLA's Dividend Comparisons



Companies with similar EPS from Cont. Operations no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %EPS from Cont. Operations for the quarter ending Sep 30 2023
Shockwave Medical Inc -2.06%$ -2.062 
Corcept Therapeutics Inc-3.13%$ -3.125 
Viatris Inc -3.45%$ -3.448 
Henry Schein Inc-3.64%$ -3.636 
Universal Health Services Inc -3.97%$ -3.968 
National Research Corporation-5.88%$ -5.882 
Mettler toledo International Inc -5.99%$ -5.990 
The Pennant Group Inc -6.25%$ -6.250 
Quest Diagnostics Inc-9.55%$ -9.545 
Charles River Laboratories International inc -10.53%$ -10.526 
Carlisle Companies Incorporated-11.00%$ -10.998 
Zimmer Biomet Holdings Inc -15.22%$ -15.217 
Stryker Corp-15.74%$ -15.741 
Tenet Healthcare Corp-18.18%$ -18.182 
Amgen Inc -19.45%$ -19.451 
Hologic Inc-22.07%$ -22.070 
Regeneron Pharmaceuticals Inc -22.99%$ -22.989 
Zynex inc -23.08%$ -23.077 
Dariohealth Corp -23.44%$ -23.438 
Pediatrix Medical Group Inc -25.71%$ -25.714 
Entera Bio Ltd -27.27%$ -27.273 
U S Physical Therapy Inc-29.17%$ -29.167 
Avantor Inc -36.00%$ -36.000 
Ufp Technologies Inc -40.70%$ -40.698 
Biomx Inc -43.48%$ -43.478 
Laboratory Corporation Of America Holdings-45.78%$ -45.780 
Pacific Health Care Organization Inc -50.00%$ -50.000 
Royalty Pharma Plc-50.00%$ -50.000 
Staar Surgical Company-52.38%$ -52.381 
Repligen Corp-54.79%$ -54.795 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com